Table 5.

Outcomes across VDZ versus non-biologic treated patients with anastomosis [with and without ostomy].

	Anastomosis with temporary ostomy				Anastomosis, no ostomy
	[ALL]	No bio	VDZ	p	[ALL]	No bio	VDZ	p
	N = 137	N = 122	N = 15		N = 328	N = 318	N = 10
Intra-abdominal sepsis	18 [13.1%]	15 [12.3%]	3 [20.0%]	0.418	29 [8.90%]	29 [9.18%]	0 [0.00%]	0.609
Intra-abdominal abscess	11 [8.03%]	8 [6.56%]	3 [20.0%]	0.103	24 [7.32%]	24 [7.55%]	0 [0.00%]	1.000
Leak	9 [6.57%]	9 [7.38%]	0 [0.00%]	0.597	9 [2.76%]	9 [2.85%]	0 [0.00%]	1.000
Superficial wound infection	12 [8.76%]	12 [9.84%]	0 [0.00%]	0.361	19 [5.79%]	18 [5.66%]	1 [10.0%]	0.454
90-day mortality	0 [0.00%]	0 [0.00%]	0 [0.00%]	.	0 [0.00%]	0 [0.00%]	0 [0.00%]	.
90-day ileus	48 [35.0%]	42 [34.4%]	6 [40.0%]	0.888	85 [25.9%]	83 [26.1%]	2 [20.0%]	1.000
Return OR 90 days	19 [13.9%]	17 [13.9%]	2 [13.3%]	1.000	13 [3.96%]	13 [4.09%]	0 [0.00%]	1.000
Readmit 90 days	43 [31.4%]	37 [30.3%]	6 [40.0%]	0.556	42 [12.8%]	41 [12.9%]	1 [10.0%]	1.000
Any infectious complication	43 [31.4%]	39 [32.0%]	4 [26.7%]	0.776	60 [18.3%]	58 [18.2%]	2 [20.0%]	1.000
Non-surgical infectious complication	21 [15.3%]	20 [16.4%]	1 [6.67%]	0.467	25 [7.65%]	24 [7.57%]	1 [10.0%]	0.554
Surgical infectious complication	26 [19.1%]	23 [19.0%]	3 [20.0%]	1.000	44 [13.4%]	43 [13.5%]	1 [10.0%]	1.000

VDZ, vedolizumab; No bio, no biologic treatment; OR, operating room.